| 0 | 💬 0 |
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-01-10 | #antibody #clinical trial #immunotherapy #lymphoma #relapse |